Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
ER

NASDAQ · ERAS

Erasca, Inc.

Healthcare · Biotechnology

$15.88

Down-$0.15 (-0.94%)

Updated Sep 12, 2026, 8:57 AM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
958.95M
P/E ratio
-7.47
Dividend yield
0.00%
52-week range
$1.53 – $24.28
Volume
2.88M
Avg. volume
1.84M

Price performance

ERAS price history

1M range · 20 trading sessions · Daily adjusted prices

ERAS closed at $15.88 after 20 trading sessions, down 13.60% for the selected period.

Last close
$15.88
Period change
-13.60%
Period low
$15.70
Period high
$19.49
Daily close
View OHLC price history
ERAS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$16.05$16.54$15.87$15.882.88M
Sep 10, 2026$15.37$17.25$15.37$16.038.25M
Sep 9, 2026$16.06$16.70$15.67$15.704.04M
Sep 8, 2026$15.88$16.65$15.68$16.284.26M
Sep 4, 2026$16.04$16.40$15.77$16.192.06M
Sep 3, 2026$16.38$16.57$16.09$16.263.76M
Sep 2, 2026$16.97$17.45$15.78$16.375.12M
Sep 1, 2026$17.58$17.95$16.68$16.766.71M
Aug 31, 2026$17.87$18.03$17.14$17.884.77M
Aug 28, 2026$19.25$19.59$18.00$18.032.89M
Aug 27, 2026$19.30$20.40$19.14$19.494.12M
Aug 26, 2026$17.57$19.50$17.24$19.157.69M
Aug 25, 2026$17.80$18.50$17.70$17.762.66M
Aug 24, 2026$18.41$18.66$16.88$17.602.24M
Aug 21, 2026$17.28$17.835$17.21$17.632.45M
Aug 20, 2026$17.59$17.77$16.92$17.082.67M
Aug 19, 2026$18.77$18.77$17.705$18.073.31M
Aug 18, 2026$18.19$18.72$17.85$18.101.92M
Aug 17, 2026$18.38$18.72$18.01$18.282.22M
Aug 14, 2026$17.50$18.465$17.30$18.382.47M

Latest ERAS news

The latest Smart Investors Daily articles mentioning ERAS.

Stock researchCompany · Overview

ERAS research

Overview

Company profile and research snapshot.

Company profile

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.50
Implied upside
—
Analysts
16
ERAS recent ratings
DateFirmRatingTarget
Aug 14, 2026B of A SecuritiesNeutral—
Aug 13, 2026GuggenheimBuy—
Aug 12, 2026HC Wainwright & Co.Buy—
Jul 20, 2026Morgan StanleyEqual-Weight—
Jul 14, 2026B of A SecuritiesNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference being held at the New York Marriott Marquis in New York, NY. Management will participate in a fireside chat on Tuesday, September 15, 2026, at 1:05 pm Easte

Yahoo · Sep 4, 2026

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

On August 24, Erasca (NASDAQ:ERAS) announced that the FDA had granted Fast Track Designation to ERAS-0015, its oral pan-RAS molecular glue, for patients with metastatic pancreatic adenocarcinoma. The designation gives Erasca more frequent contact with regulators and, if the drug keeps clearing bars, a shot at accelerated approval, priority review, and rolling review. For a […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By